Prognostic factors in lymph node-positive prostate cancer.

[1]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[2]  F. Burkhard,et al.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? , 2003, The Journal of urology.

[3]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[4]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[5]  A. Partin,et al.  Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. , 1999, The Journal of urology.

[6]  M. Soloway,et al.  Is there a role for digital rectal examination in the followup of patients after radical prostatectomy? , 1999, The Journal of urology.

[7]  J. Cheville,et al.  Dedifferentiation in the metastatic progression of prostate carcinoma , 1999, Cancer.

[8]  E. Bergstralh,et al.  Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. , 1999, The Journal of urology.

[9]  M. Blute,et al.  Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. , 1998, The Journal of urology.

[10]  S. Fosså,et al.  Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. , 1993, The Journal of urology.

[11]  E. Bergstralh,et al.  Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors , 1992, Cancer.

[12]  W. Catalona,et al.  Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. , 1992, The Journal of urology.

[13]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[14]  P. Brawn.  Histologic features of metastatic prostate cancer. , 1992, Human pathology.

[15]  P. Brawn,et al.  Stage D1 prostate carcinoma the histologic appearance of nodal metastases and its relationship to survival , 1990, Cancer.

[16]  V. Speights,et al.  The dedifferentiation of metastatic prostate carcinoma. , 1989, British Journal of Cancer.

[17]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[18]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[19]  D. Bostwick,et al.  Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.

[20]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[21]  W. Fair,et al.  Prognostic significance of antigenic heterogeneity, gleason grade, and ploidy of lymph node metastases in patients with prostate cancer , 1992, The Prostate.